Get the Stockscreener App
38.15
2.94%
1.09
After Hours:
38.15
Scholar Rock Holding Corp stock is traded at $38.15, with a volume of 734.38K.
It is up +2.94% in the last 24 hours and up +27.55% over the past month.
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
See More
Previous Close:
$37.06
Open:
$37.07
24h Volume:
734.38K
Relative Volume:
0.38
Market Cap:
$3.52B
Revenue:
$47.30M
Net Income/Loss:
$-203.85M
P/E Ratio:
-19.37
EPS:
-1.97
Net Cash Flow:
$-168.65M
1W Performance:
+36.93%
1M Performance:
+27.55%
6M Performance:
+257.54%
1Y Performance:
+218.71%
1-Day Range:
$36.64
$38.90
1-Week Range:
$25.88
$43.38
52-Week Range:
$6.76
$43.38
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
38.15 | 3.52B | 47.30M | -203.85M | -168.65M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
Scholar Rock holding sees $15.76m in stock sales by major shareholders - Investing.com
Scholar Rock set for BLA, among 14 phase III wins in October - BioWorld Online
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, Truist Financial Analyst Says - Defense World
Wedbush Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock - Defense World
Scholar Rock's chief medical officer sells $315,771 in stock - Investing.com
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Scholar Rock shares surge 26% as rival Biohaven misses SMA study goal - TradingPedia
SRRK stock soars to 52-week high, touches $40 mark By Investing.com - Investing.com South Africa
Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Quest Partners LLC - MarketBeat
Biohaven’s SMA Trial Miss Bolsters Scholar Rock Stock: Analysts Give Verdicts, Retail Watches Closely - MSN
SRRK stock soars to 52-week high, touches $40 mark - Investing.com
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study - Yahoo Finance
Why Scholar Rock shares are surging By Investing.com - Investing.com Nigeria
Scholar Rock (NASDAQ:SRRK) Stock Price Up 9.2%Still a Buy? - MarketBeat
FY2024 EPS Estimates for Scholar Rock Cut by HC Wainwright - Defense World
What is Wedbush’s Forecast for Scholar Rock FY2024 Earnings? - Defense World
Redmile Group, LLC Expands Stake in Scholar Rock Holding Corp - GuruFocus.com
OrbiMed Advisors LLC Adjusts Stake in Scholar Rock Holding Corp - GuruFocus.com
FY2024 Earnings Forecast for Scholar Rock Issued By Wedbush - MarketBeat
Analysts Set Expectations for Scholar Rock FY2024 Earnings - MarketBeat
FY2028 Earnings Forecast for Scholar Rock Issued By Wedbush - MarketBeat
HC Wainwright Comments on Scholar Rock Q3 Earnings - MarketBeat
Scholar Rock chief medical officer sells $63k in stock By Investing.com - Investing.com Australia
Scholar Rock chief medical officer sells $63k in stock - Investing.com
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2024 Earnings Call Transcript - Insider Monkey
Creative Planning Invests $115,000 in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and Promising Study Results - GuruFocus.com
Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
FMR LLC Bolsters Position in Scholar Rock Holding Corp - GuruFocus.com
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress - citybiz
Scholar Rock Holding Corp Reports Q3 2024 Net Loss of $64.5 Mill - GuruFocus.com
Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Scholar Rock Holding Co. (NASDAQ:SRRK) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Scholar Rock Holding Co. (NASDAQ:SRRK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Scholar Rock (NASDAQ:SRRK) Earns “Outperform” Rating from Wedbush - Defense World
Scholar Rock (SRRK) Scheduled to Post Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Scholar Rock Holdi - GuruFocus.com
Scholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush - MarketBeat
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin - BioSpace
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - BioSpace
abrdn plc Raises Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat
Scholar Rock to Participate in Upcoming Investor Conferences - BioSpace
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting - sharewise
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39 - Business Wire
Stocks to Watch: Bitcoin, technology companies, medical research lead Nasdaq (Oct. 21-25) - The News Record
Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by E. Ohman J or Asset Management AB - MarketBeat
Dow Jones, S&P 500 fall amid rising oil prices; Scholar Rock jumps 300%, Apple and insurance stocks dip - MSN
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
Scholar Rock Closes of Full Exercise of Option to Purchase Additional Shares in Public Offering - citybiz
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering - Business Wire
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? - Yahoo Finance
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):